Tobam Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)

Tobam lowered its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 64.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,388 shares of the biotechnology company's stock after selling 11,834 shares during the quarter. Tobam's holdings in United Therapeutics were worth $1,969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of UTHR. Wealthfront Advisers LLC increased its position in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock valued at $6,462,018,000 after acquiring an additional 18,313,424 shares during the last quarter. Vanguard Group Inc. increased its position in United Therapeutics by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after buying an additional 32,213 shares in the last quarter. FMR LLC increased its position in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after buying an additional 393,777 shares in the last quarter. Geode Capital Management LLC increased its position in United Therapeutics by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after buying an additional 44,277 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in United Therapeutics by 0.8% in the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after buying an additional 7,710 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. This trade represents a 22.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 12,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares of the company's stock, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,500 shares of company stock valued at $20,828,390. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Down 1.0%

United Therapeutics stock traded down $2.79 during midday trading on Friday, reaching $283.35. 564,424 shares of the stock traded hands, compared to its average volume of 452,793. The stock's fifty day moving average is $300.50 and its 200-day moving average is $330.53. United Therapeutics Co. has a 12 month low of $266.98 and a 12 month high of $417.82. The stock has a market cap of $12.78 billion, a P/E ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. During the same period in the prior year, the company earned $6.17 earnings per share. The firm's revenue was up 17.2% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.